Humacyte Inc. has announced the publication of long-term safety and efficacy results for Symvess, an acellular tissue engineered vessel, in the repair of extremity arterial trauma. The results, published in the Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT), represent the first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit. The study followed patients for up to 36 months, demonstrating high limb salvage rates, low infection rates, and no unprovoked structural failures. Symvess is indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed and autologous vein graft is not feasible.